Nuvectis Pharma (NVCT) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Pipeline overview and development progress

• Two targeted oncology drugs, NXP-800 and NXP-900, are in clinical development, each with distinct mechanisms and disease targets.

• NXP-800 is in phase I-B for platinum-resistant ARID1A-mutated ovarian cancer and cholangiocarcinoma, with a data update expected in fall on 12–15 patients.

• NXP-900 is in phase I-A dose escalation, currently in the 150mg group, with phase I-B planned for early 2025.

• Both drugs were in-licensed from leading UK research institutions.

• Management team has a strong track record of drug approvals in oncology.

Clinical and preclinical data highlights

• NXP-800 showed encouraging early efficacy (1 partial response, 2 stable disease in 3 patients) and manageable safety after protocol adjustments for thrombocytopenia.

• Preclinical models demonstrated NXP-800 outperformed platinum chemotherapy in ARID1A-mutated ovarian cancer and showed potency in cholangiocarcinoma and endometrial models.

• Fast Track and orphan drug designations were granted for NXP-800 in platinum-resistant ARID1A-mutated ovarian cancer.

• NXP-900 is a highly selective Src inhibitor, designed to overcome side effects seen with earlier multi-kinase inhibitors.

• NXP-900 demonstrated mechanistic advantages in shutting down Src kinase activity and promising preclinical synergy with EGFR and ALK inhibitors.

Strategic focus and market opportunities

• ARID1A mutation is prevalent across several tumor types, offering potential for future tumor-agnostic indications.

• NXP-900 targets squamous cell cancers and is being positioned for combination strategies in non-small cell lung cancer to address EGFR and ALK resistance.

• Addressable patient populations are significant, especially in lung, head and neck, and esophageal cancers.

• The company maintains a modular, stepwise approach to clinical expansion, focusing on establishing initial indications before broader applications.